BMY Overview
Upcoming Projects (BMY)
-
Don’t see a project related to the company you care about? Create your own!
Executed Projects (BMY)
-
A Third Look: Delving into the recent data published in JAMA Dermatology from the Phase 2 clinical trial of cendakimab in patients with atopic dermatitis
Ticker: BMY
Executed On: Aug 27, 2024 at 06:15 PM EDT -
A Second Look: Delving into the recent data published in JAMA Dermatology from the Phase 2 clinical trial of cendakimab in patients with atopic dermatitis
Ticker: BMY
Executed On: Aug 21, 2024 at 03:00 PM EDT -
Delving into the recent data published in JAMA Dermatology from the Phase 2 clinical trial of cendakimab in patients with atopic dermatitis
Ticker: BMY
Executed On: Aug 14, 2024 at 01:30 PM EDT -
Discussing the recent approval of Bristol Myers' Krazati for the treatment of colorectal cancer
Ticker: BMY
Executed On: Jun 26, 2024 at 06:00 PM EDT -
A Third Look: Evaluating the four-year Sotyktu (deucravacitinib) data in plaque psoriasis.
Ticker: BMY
Executed On: Jun 06, 2024 at 12:00 PM EDT -
A Second Look: Evaluating the four-year Sotyktu (deucravacitinib) data in plaque psoriasis.
Ticker: BMY
Executed On: May 22, 2024 at 06:30 PM EDT -
Evaluating the four-year Sotyktu (deucravacitinib) data in plaque psoriasis.
Ticker: BMY
Executed On: May 22, 2024 at 03:00 PM EDT -
A Third Look: Discussing the Emergent 4 and Emergent 5 trials of KarXT
Ticker: BMY
Executed On: May 22, 2024 at 10:30 AM EDT -
Looking at the long term data of Sotyktu for plaque psoriasis
Ticker: BMY
Executed On: May 08, 2024 at 05:00 PM EDT -
A Second Look: Discussing the Emergent 4 and Emergent 5 trials of KarXT
Ticker: BMY
Executed On: Apr 26, 2024 at 02:00 PM EDT -
Discussing the Emergent 4 and Emergent 5 trials of KarXT
Ticker: BMY
Executed On: Apr 25, 2024 at 04:30 PM EDT -
Discussing the recent approval of Breyanzi (lisocabtagene maraleucel; liso-cel), a CAR-T cell therapy for the treatment of CLL and SLL.
Ticker: BMY
Executed On: Apr 18, 2024 at 10:00 AM EDT -
A Second Opinion: Investigating the prescription habits of CAR-T products for the treatment of multiple myeloma.
Ticker: BMY
Executed On: Mar 28, 2024 at 12:00 PM EDT -
A Third Look: Discussing the Phase 3 DAYBREAK study of Zeposia (ozanimod), an oral medication that has been FDA approved for treatment of Multiple Sclerosis.
Ticker: BMY
Executed On: Mar 27, 2024 at 05:00 PM EDT -
A Second Look: Discussing the Phase 3 DAYBREAK study of Zeposia (ozanimod), an oral medication that has been FDA approved for treatment of Multiple Sclerosis.
Ticker: BMY
Executed On: Mar 26, 2024 at 03:00 PM EDT -
Discussing the Phase 3 DAYBREAK study of Zeposia (ozanimod), an oral medication that has been FDA approved for treatment of Multiple Sclerosis.
Ticker: BMY
Executed On: Mar 26, 2024 at 10:00 AM EDT -
A Third Look: Delving into the recent results of the phase 2b APIPPRA clinical trial of Orencia (Abatacept) in patients with a high risk of developing rheumatoid arthritis
Ticker: BMY
Executed On: Mar 22, 2024 at 02:00 PM EDT -
Investigating the prescription habits of CAR-T products for the treatment of multiple myeloma.
Ticker: BMY
Executed On: Mar 19, 2024 at 11:00 AM EDT -
Discussing the results from the CheckMate-901 trial of the Opdivo (nivolumab), cisplatin, and gemcitabine combo for urothelial carcinoma
Ticker: BMY
Executed On: Mar 11, 2024 at 03:15 PM EDT -
A Second Look: Delving into the recent results of the phase 2b APIPPRA clinical trial of Orencia (Abatacept) in patients with a high risk of developing rheumatoid arthritis
Ticker: BMY
Executed On: Mar 08, 2024 at 12:15 PM EST -
Delving into the recent results of the phase 2b APIPPRA clinical trial of Orencia (Abatacept) in patients with a high risk of developing rheumatoid arthritis
Ticker: BMY
Executed On: Mar 07, 2024 at 02:30 PM EST -
A Third look at Viz.AIs new artificial intelligence algorithm for earlier detection and management of hypertrophic cardiomyopathy
Tickers: VIZ.AI, BMY, CYTK
Executed On: Feb 28, 2024 at 08:30 AM EST -
A Second look at Viz.AIs new artificial intelligence algorithm for earlier detection and management of hypertrophic cardiomyopathy
Tickers: VIZ.AI, BMY, CYTK
Executed On: Jan 26, 2024 at 08:30 AM EST -
A look at Viz.AIs new artificial intelligence algorithm for earlier detection and management of hypertrophic cardiomyopathy
Tickers: VIZ.AI, BMY, CYTK
Executed On: Jan 25, 2024 at 04:00 PM EST -
A Third Look: Investigating Bristol Myers Squibbs' BMS-986278 for the treatment of PPF
Ticker: BMY
Executed On: Jan 17, 2024 at 03:00 PM EST -
A Second Look: Investigating Bristol Myers Squibbs' BMS-986278 for the treatment of PPF
Ticker: BMY
Executed On: Jan 12, 2024 at 12:00 PM EST -
Investigating Bristol Myers Squibbs' BMS-986278 for the treatment of PPF
Ticker: BMY
Executed On: Jan 11, 2024 at 10:00 AM EST -
A Second Look: Discussing the Phase 1/2 study to assessing Mezigdomide in patients with multiple myeloma
Ticker: BMY
Executed On: Nov 07, 2023 at 09:00 AM EST -
Discussing the Phase 1/2 study to assessing Mezigdomide in patients with multiple myeloma
Ticker: BMY
Executed On: Oct 04, 2023 at 05:00 PM EDT -
A Third Opinion: Discussing the standard of care and/or the potential of Camzyos a medication for the treatment of obstructive (HCM) from Bristol Myers with prescribers
Ticker: BMY
Executed On: Sep 28, 2023 at 10:30 AM EDT -
A Second Opinion: Discussing the standard of care and/or the potential of Camzyos a medication for the treatment of obstructive (HCM) from Bristol Myers with prescribers
Ticker: BMY
Executed On: Sep 27, 2023 at 05:00 PM EDT -
Discussing the standard of care and/or the potential of Camzyos a medication for the treatment of obstructive (HCM) from Bristol Myers with prescribers
Ticker: BMY
Executed On: Sep 22, 2023 at 04:00 PM EDT -
A Third Opinion: Digging into the TRANSCEND studies for Bristol Myers' Breyanzi (lisocabtagene maraleucel) in follicular and mantle cell lymphoma
Ticker: BMY
Executed On: Jul 14, 2023 at 10:00 AM EDT -
A Second Opinion: Digging into the TRANSCEND studies for Bristol Myers' Breyanzi (lisocabtagene maraleucel) in follicular and mantle cell lymphoma
Ticker: BMY
Executed On: Jul 12, 2023 at 02:00 PM EDT -
Digging into the TRANSCEND studies for Bristol Myers' Breyanzi (lisocabtagene maraleucel) in follicular and mantle cell lymphoma
Ticker: BMY
Executed On: Jun 27, 2023 at 11:30 AM EDT -
Discussing new data available from ASCO 2023 on MDS with a focus on Bristol Myers' Reblozyl (luspatercept) COMMANDS trial and Geron's imetelstat IMerge Phase 2/3 study in patients with LR-MDS.
Tickers: BMY, GERN
Executed On: Jun 20, 2023 at 05:00 PM EDT -
Discussing metastatic melanoma, and known treatment medication such as Opdualag, a premixed combination of (nivolumab and relatlimab-rmbw) used through intravenous infusions.
Ticker: BMY
Executed On: Feb 09, 2023 at 11:00 AM EST -
A Second Look: Discussing the KarMMa Phase 2 Cohorts 2a and 2c Study Results of Abecma(idecabtagene vicleucel) in R/R multiple myeloma presented at the ASH 2022 conference
Tickers: TSVT, BMY
Executed On: Jan 09, 2023 at 06:15 PM EST -
Discussing the KarMMa Phase 2 Cohorts 2a and 2c Study Results of Abecma(idecabtagene vicleucel) in R/R multiple myeloma presented at the ASH 2022 conference
Tickers: TSVT, BMY
Executed On: Dec 19, 2022 at 03:00 PM EST -
A fourth look: Discussing the efficacy and response to treat of Psoriasis with deucravacitinib
Ticker: BMY
Executed On: Oct 27, 2022 at 10:00 AM EDT -
A Third look: Discussing the efficacy and response to treat of Psoriasis with deucravacitinib
Ticker: BMY
Executed On: Oct 26, 2022 at 06:30 PM EDT -
A second look: Discussing the efficacy and response to treat of Psoriasis with deucravacitinib
Ticker: BMY
Executed On: Oct 26, 2022 at 04:30 PM EDT -
Examining the clinical landscape of renal disease and the potential of anticoagulant therapies in this space for the prevention of cardiovascular events, including Merck's MK-2060.
Tickers: MRK, PFE, BMY
Executed On: Oct 03, 2022 at 02:00 PM EDT -
A third look at the clinical landscape for prevention of major cardiovascular events, including an in depth discussion about the phase 2 data of Milvexian, a factor XIa inhibitor
Tickers: BMY, JNJ
Executed On: Sep 22, 2022 at 04:30 PM EDT -
Discussing the efficacy and response to treat of Psoriasis with deucravacitinib
Ticker: BMY
Executed On: Sep 22, 2022 at 04:30 PM EDT -
A second look at the clinical landscape for prevention of major cardiovascular events, including an in depth discussion about the phase 2 data of Milvexian, a factor XIa inhibitor
Tickers: BMY, JNJ
Executed On: Sep 15, 2022 at 07:00 PM EDT -
Looking at the clinical landscape for prevention of major cardiovascular events, including an in depth discussion about the phase 2 data of Milvexian, an anticoagulation medication in development by Bristol Myers and Janssen Pharmaceuticals
Tickers: BMY, JNJ
Executed On: Sep 12, 2022 at 02:00 PM EDT -
A look at the use of ELIQUIS, Xarelto, and other blood thinners for cardiovascular disease and atrial fibrillation
Tickers: BMY, JNJ, BAYN.XSWX
Executed On: Aug 26, 2022 at 01:30 PM EDT -
A Final Look at the efficacy of Mavacamten as a treatment of hypertrophic cardiomyopathy
Tickers: BMY, LIAN
Executed On: Jul 13, 2022 at 04:15 PM EDT -
A Third Look at the efficacy of Mavacamten as a treatment of hypertrophic cardiomyopathy
Tickers: BMY, LIAN
Executed On: Jul 08, 2022 at 12:00 PM EDT -
A Second Look at the efficacy of Mavacamten as a treatment of hypertrophic cardiomyopathy
Ticker: BMY
Executed On: Jun 30, 2022 at 03:00 PM EDT -
A Look at the efficacy of Mavacamten as a treatment of hypertrophic cardiomyopathy
Ticker: BMY
Executed On: Jun 28, 2022 at 11:30 AM EDT -
Key Takeaways from AACR 2022: A conversation with an oncologist who attended the conference
Ticker: BMY
Executed On: May 03, 2022 at 08:00 AM EDT -
A Third View: Discussing the potential of Mavacamten, currently under development for the treatment of symptomatic obstructive hypertrophic cardiomyopathy
Ticker: BMY
Executed On: Apr 27, 2022 at 12:00 PM EDT -
A Second View: Discussing the potential of Mavacamten, currently under development for the treatment of symptomatic obstructive hypertrophic cardiomyopathy
Ticker: BMY
Executed On: Apr 20, 2022 at 04:00 PM EDT -
A Third Opinion: Discussing the standard of care and the use of Zeposia (ozanimod) in treating MS
Ticker: BMY
Executed On: Apr 20, 2022 at 03:00 PM EDT -
A Third Opinion: Discussing the standard of care and the use of Zeposia (ozanimod) in treating Ulcerative Colitis
Ticker: BMY
Executed On: Apr 19, 2022 at 09:00 AM EDT -
A Second Opinion: Discussing the standard of care and the use of Zeposia (ozanimod) in treating Ulcerative Colitis
Ticker: BMY
Executed On: Apr 14, 2022 at 01:30 PM EDT -
Discussing the potential of Mavacamten, currently under development for the treatment of symptomatic obstructive hypertrophic cardiomyopathy.
Ticker: BMY
Executed On: Apr 07, 2022 at 01:00 PM EDT -
Discussing the standard of care and the use of Zeposia (ozanimod) in treating Ulcerative Colitis
Ticker: BMY
Executed On: Apr 06, 2022 at 05:00 PM EDT -
A Second Opinion: Discussing the standard of care and the use of Zeposia (ozanimod) in treating MS
Ticker: BMY
Executed On: Apr 05, 2022 at 02:00 PM EDT -
Discussing the standard of care and the use of Zeposia (ozanimod) in treating MS
Ticker: BMY
Executed On: Mar 28, 2022 at 08:00 PM EDT -
Discussion on BCMA targeted therapies in multiple myeloma - second look
Tickers: LEGN, TSVT, BMY, JNJ
Executed On: Feb 23, 2022 at 07:00 PM EST -
A look at upcoming Cilta-cel PDUFA and other BCMA directed therapies
Tickers: LEGN, BMY, TSVT, JNJ
Executed On: Feb 17, 2022 at 03:00 PM EST
Upcoming & Overdue Catalysts (BMY)
-
Don’t see a catalyst related to the company you care about? Create your own!
Strategic Initiatives (BMY)
-
Don’t see a strategic initiative related to the company you care about? Create your own!
